We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

21 hedge funds and large institutions have $346K invested in LakeShore Biopharma Warrants in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

3.25% less ownership

Funds ownership: 5.3% → 2.05% (-3.3%)

9% less funds holding

Funds holding: 23 → 21 (-2)

31% less capital invested

Capital invested by funds: $501K → $346K (-$155K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
2
Increased
–
Reduced
2
Closed
4
Calls
$75K
Puts
–
Net Calls
+$75K
Net Calls Change
-$30K

Top Buyers

Rank Fund Capital Flow
1
OCM
Ovata Capital Management
Hong Kong
+$9.46K
2
TSS
Two Sigma Securities
New York
+$1.1K

Top Sellers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
-$66.4K
2
SCM
Shaolin Capital Management
Florida
-$6.71K
3
EAM
Exos Asset Management
New York
-$4.4K
4
CAC
Cowen and Company
New York
-$1.21K
5
CS
Clear Street
New York
-$84
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$88K – – –
VAM
2
Valliance Asset Management
Hong Kong
$49.6K – – –
BP
3
BFAM Partners
Hong Kong
$44K – – –
Jane Street
4
Jane Street
New York
$32.9K – – –
FC
5
Finepoint Capital
Massachusetts
$24.2K – – –
BCL
6
Bracebridge Capital LLC
Massachusetts
$15.4K – – –
CAC
7
Cowen and Company
New York
$14.1K -$1.21K -19,150 -8%
HCM
8
Highbridge Capital Management
New York
$13.2K – – –
OCM
9
Ovata Capital Management
Hong Kong
$9.91K +$9.46K +150,000 New
QGA
10
Q Global Advisors
Texas
$9K – – –
WA
11
Whitebox Advisors
Minnesota
$8.26K – – –
Calamos Advisors
12
Calamos Advisors
Illinois
$7.21K – – –
Walleye Capital
13
Walleye Capital
New York
$6.6K – – –
SCM
14
Saba Capital Management
New York
$6.43K – – –
CF
15
Cantor Fitzgerald
New York
$5.08K – – –
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$4.94K – – –
CS
17
Clear Street
New York
$3.18K -$84 -1,326 -3%
MC
18
Meteora Capital
Florida
$1.65K – – –
TSS
19
Two Sigma Securities
New York
$1.15K +$1.1K +17,400 New
SIA
20
SkyView Investment Advisors
New Jersey
$1K – – –
AA
21
Ancora Advisors
Ohio
$334 – – –
HIM
22
HGC Investment Management
Ontario, Canada
$331 – – –
LP
23
LMR Partners
United Kingdom
– -$66.4K -1,052,461 Closed
SCM
24
Shaolin Capital Management
Florida
– -$6.71K -76,200 Closed
EAM
25
Exos Asset Management
New York
– -$4.4K -50,000 Closed
1
2

LSBPW Hedge Fund Activity: Q3 2024 in Review

21 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q3 2024, worth a combined $346K — down 31% from $501K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of LSBPW and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Ovata Capital Management, opening a new position worth an estimated $9.46K. The largest seller was LMR Partners, exiting entirely with an estimated $66.4K sold.

  • 21 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q3 2024, down from 23 in Q2 2024.
  • Funds reported $346K of LakeShore Biopharma Warrants stock for Q3 2024, down 31% quarter-over-quarter.
  • 2 funds opened new LakeShore Biopharma Warrants positions in Q3 2024 and 4 closed out, a net change of -2 holders.
  • The largest LakeShore Biopharma Warrants buyer in Q3 2024 was Ovata Capital Management, an estimated $9.46K added.
  • The largest LakeShore Biopharma Warrants seller in Q3 2024 was LMR Partners, an estimated $66.4K sold.

Based on aggregated 13F filings for Q3 2024.